Sub-lingual immunotherapy: world allergy organization position paper 2009. - Wikidata - awgldk - TriplyDB

Sub-lingual immunotherapy: world allergy organization position paper 2009.

Sub-lingual immunotherapy: world allergy organization position paper 2009.

http://www.wikidata.org/entity/Q55527154

about

Critical appraisal of Timothy grass pollen extract GRAZAX in the management of allergic rhinitis.Facing Hymenoptera Venom Allergy: From Natural to Recombinant Allergens Efficacy and safety of ragweed sublingual immunotherapy in Canadian patients with allergic rhinoconjunctivitis Sublingual immunotherapy: World Allergy Organization position paper 2013 update.A multicenter, randomized, parallel-group trial assessing compliance, tolerability, safety, and efficacy to treatment with grass allergy tablets in 261 patients with grass pollen rhinoconjunctivitis.Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma.Magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on pollen exposure The efficacy and safety of the Timothy grass allergy sublingual immunotherapy tablet in Canadian adults and children.Current status and future perspectives of immunotherapy in Latin America and Cuba.History of the world allergy organization: innovation in continuity 2008-2009 Sublingual Immunotherapy: Clinical Indications in the WAO-SLIT Position Paper.Sublingual versus subcutaneous immunotherapy: patient adherence at a large German allergy center.Effectiveness of Specific Sublingual Immunotherapy in Korean Patients with Atopic Dermatitis.Arguing the misconceptions in allergen-specific immunotherapy.SQ house dust mite (HDM) SLIT-tablet provides clinical improvement in HDM-induced allergic rhinitis.The efficiency of peptide immunotherapy for respiratory allergy.Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma.Allergen immunotherapy: routes, safety, efficacy, and mode of action.Investigational new drugs for allergic rhinitis.Utility and Comparative Efficacy of Recombinant Allergens Versus Allergen Extract.Chinese Guideline on allergen immunotherapy for allergic rhinitis.Biological mechanisms underlying the clinical effects of allergen-specific immunotherapy in asthmatic children.Negative clinical results from a randomised, double-blind, placebo-controlled trial evaluating the efficacy of two doses of immunologically enhanced, grass subcutaneous immunotherapy despite dose-dependent immunological response.CSACI position statement: prescribing sublingual immunotherapy tablets for aeroallergens.Applicability of evidence from previous systematic reviews on immunotherapy in current practice of childhood asthma treatment: a GRADE (Grading of Recommendations Assessment, Development and Evaluation) systematic review.[Adherence in specific immunotherapy].Clinical and immunological responses of dust mite sensitive, atopic dogs to treatment with sublingual immunotherapy (SLIT)

P2860

Q26775905-E1D4DB45-40BE-4AD9-961F-24BE406BFF69 Q26799910-6329BC3B-F63A-4510-8BFF-E07C33524EB6 Q28390024-5D9D2AFE-BE70-43EE-A8B8-C018B051CE74 Q30440195-71B065E9-0386-482A-A5D6-27E83C370299 Q30472704-2F29B107-77F4-45BD-A691-43ABED659FF8 Q33586188-4BB543E1-1DEE-47E6-9B6A-794BA3FA87AF Q34375745-D9A7189D-05DF-4A67-AFA6-854F39EF0228 Q35040990-8F25BEE5-0607-4BC7-AA75-648611A4DBC8 Q35078784-546B7B6A-8FDD-40BD-9398-3C38CCDD10C2 Q35187367-FD5F7064-87FB-44B7-8462-83BA6857E4BA Q36370925-5A70285B-2EBA-4D0E-A3F4-E0C167CA146B Q36834756-50275D4C-FB21-4F9E-A1BD-84B1EC34A265 Q37573127-DF7D5C7F-BAC7-47EF-B339-C3306E0E04B1 Q37653991-F32192C8-61EA-4FE9-9C05-14E205310754 Q38217592-BA34D57B-6941-4304-88FE-3565D700B49C Q38703818-69FB283D-2CDF-4B7B-B322-DD1D65C12F9F Q38744223-03492B88-644C-4382-BED3-9AAB2EA818FE Q38870647-A7F04843-D2A4-4CC7-8FAA-897720DD6356 Q38912244-048B67CB-57A6-436C-8A04-05B35837AF33 Q39111947-543178D5-CFD3-46E8-9F76-C43B3D9E170B Q40087434-57DB17E6-7C57-4C71-AA6D-E34E18B17E1C Q47149942-8A8A1B52-7B86-4EE9-81DC-56AF3C7E7C94 Q47429419-602B725F-FD37-409A-AD7C-017180AEBCE0 Q48095700-52F90698-B8E5-4BAA-9DBC-35176F1E9EE0 Q49163817-1257C160-6594-4F6F-AB13-EA5457ECCF49 Q49485552-7A0C8AEA-D311-4105-B0AB-AFCFAA1F24EE Q52718381-EBD29A38-8AB6-4EF1-A500-9A1264E017B3 Q58796312-A70094FA-BFCC-4E41-9CDD-861515302767

P2860

Sub-lingual immunotherapy: world allergy organization position paper 2009.

http://www.wikidata.org/entity/Q55527154

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Sub-lingual immunotherapy: world allergy organization position paper 2009.

@en

Sub-lingual immunotherapy: world allergy organization position paper 2009.

@nl

type

label

Sub-lingual immunotherapy: world allergy organization position paper 2009.

@en

Sub-lingual immunotherapy: world allergy organization position paper 2009.

@nl

prefLabel

Sub-lingual immunotherapy: world allergy organization position paper 2009.

@en

Sub-lingual immunotherapy: world allergy organization position paper 2009.

@nl

P1433

Q55527154-591C9BA2-1D94-410F-B27A-301B4F93FEFA

P1476

Q55527154-C4CD8943-A742-4F1F-A715-E1F3B5710F18

P2093

Q55527154-05763B64-8EB3-478F-8B23-3BE2BCD7DFFF

Q55527154-0F3D220F-70D2-4385-B3DD-2D333EF8DF76

Q55527154-1882D2E5-3139-4348-B8EC-D035B43905FA

Q55527154-1AE23007-2A01-4E3D-8124-C576F19E2600

Q55527154-27BBC8F1-E32A-4519-BF0B-910497DCF27B

Q55527154-297B3DE3-A733-4C70-875C-F0D0EFAD2CE1

Q55527154-47411547-CB08-4639-A362-4A75591A67E9

Q55527154-4FDB5A87-5257-4DF3-8ACF-3C29CEFC6AC5

Q55527154-5223E321-A01E-4A0A-8295-F37508FD0E5A

Q55527154-527D4794-7C97-4375-99BE-EC9B324CA44C

P2860

Q55527154-0087D160-DCF3-445A-8C12-D24D2C41745C

Q55527154-04AEF621-CF04-4881-9D86-E811AD38ABB4

Q55527154-04C70A30-78C5-46E3-90AA-72684EE690B0

Q55527154-052CAB1C-EDE3-4BC2-B369-862DA2CB8CC6

Q55527154-077634C6-57D1-4F71-870A-835D78096F51

Q55527154-09A71DB9-D5C4-4B93-8301-C82FA0E0E69B

Q55527154-09AE0D0D-1FF1-43C4-ADDB-DCAD9A04FB60

Q55527154-0AE3D3EE-C6D6-47C3-8B32-F74217F745FD

Q55527154-0C4732E7-187D-4465-AE9E-3CA70F77351C

Q55527154-0C9EFC9D-68D0-419D-B8DB-4C2B21EB3E19

P2888

Q55527154-ADA96F28-FB33-47FD-8998-A464F777DD49

P304

Q55527154-E9361E2D-9032-4C6F-A80C-381A5FEEED78

P31

Q55527154-A43BFFBC-6226-4CCE-AC5C-4B84060B5208

P356

Q55527154-3DE33E3B-88C9-4FBD-8BEC-FD0E5A035597

P433

Q55527154-05C361AE-0278-46C6-AFAD-D4E1530D9163

P478

Q55527154-8EB252E7-0088-40C3-A3A8-86DE0DB719B2

P50

Q55527154-1E4F6173-FC90-4F9C-AF3A-917B2EE878C7

Q55527154-69E8DF55-0C4F-4CFD-A7B0-54D5307250B5

Q55527154-A07A6AB5-BAAD-41A6-A441-1F508364C971

Q55527154-DB0A0273-A6C9-4FE0-8D67-8E70EC7D789E

Q55527154-E906DB43-EEF1-480A-9240-D64DA050AE16

P577

Q55527154-89E64D8A-BA99-4AD3-84F3-91CB32D8EFE3

P6179

Q55527154-2895FC00-9954-484E-91C7-6293D13DB5FE

P698

Q55527154-4BBC78D1-47F8-40FB-83D3-BD9E2F3C6D8C

P921

Q55527154-19D81A05-ABF3-4BE1-AA30-B4720EFA951F

P932

Q55527154-5EC8DAB5-B3D5-45F1-B758-0BDB59C43439

P356

WOX.0B013E3181C6C379

P1433

The World Allergy Organization Journal

P1476

Sub-lingual immunotherapy: world allergy organization position paper 2009.

@en

P2093

Carlos E Baena-Cagnani

http://www.w3.org/2001/XMLSchema#string

Dennis K Ledford

http://www.w3.org/2001/XMLSchema#string

Enrico Compalati

http://www.w3.org/2001/XMLSchema#string

Erkka J Valovirta

http://www.w3.org/2001/XMLSchema#string

Harold S Nelson

http://www.w3.org/2001/XMLSchema#string

Jan L Brozek

http://www.w3.org/2001/XMLSchema#string

Jean Bousquet

http://www.w3.org/2001/XMLSchema#string

Linda S Cox

http://www.w3.org/2001/XMLSchema#string

Luis Delgado

http://www.w3.org/2001/XMLSchema#string

Nelson Rosario Filho

http://www.w3.org/2001/XMLSchema#string

P2860

Allergen injection immunotherapy for seasonal allergic rhinitis

Allergen immunotherapy for asthma

Grading quality of evidence and strength of recommendations

What is meant by intention to treat analysis? Survey of published randomised controlled trials

T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity

Systems for grading the quality of evidence and the strength of recommendations II: pilot study of a new system

Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment

The diagnosis and management of rhinitis: an updated practice parameter

P2888

wox.0b013e3181c6c379

P304

233-281

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/WOX.0B013E3181C6C379

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Torsten Zuberbier

Giorgio Walter Canonica

Giovanni Passalacqua

P577

2009-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1048406222

http://www.w3.org/2001/XMLSchema#string

P698

23268425

http://www.w3.org/2001/XMLSchema#string

P921

P932

3488881

http://www.w3.org/2001/XMLSchema#string